- Home
- DVN vs BIIB Comparison
DVN vs BIIB Comparison
Compare DVN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVN
- BIIB
- Stock Information
- Founded
- DVN 1971
- BIIB 1978
- Country
- DVN United States
- BIIB United States
- Employees
- DVN N/A
- BIIB N/A
- Industry
- DVN Oil & Gas Production
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- DVN Energy
- BIIB Health Care
- Exchange
- DVN Nasdaq
- BIIB Nasdaq
- Market Cap
- DVN 25.4B
- BIIB 25.1B
- IPO Year
- DVN N/A
- BIIB 1991
- Fundamental
- Price
- DVN $34.88
- BIIB $157.96
- Analyst Decision
- DVN Buy
- BIIB Buy
- Analyst Count
- DVN 21
- BIIB 25
- Target Price
- DVN $51.50
- BIIB $258.57
- AVG Volume (30 Days)
- DVN 8.0M
- BIIB 1.6M
- Earning Date
- DVN 11-05-2024
- BIIB 10-30-2024
- Dividend Yield
- DVN 4.03%
- BIIB N/A
- EPS Growth
- DVN N/A
- BIIB 10.05
- EPS
- DVN 5.41
- BIIB 11.06
- Revenue
- DVN $14,529,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- DVN $9.80
- BIIB N/A
- Revenue Next Year
- DVN $8.11
- BIIB N/A
- P/E Ratio
- DVN $6.65
- BIIB $14.41
- Revenue Growth
- DVN N/A
- BIIB N/A
- 52 Week Low
- DVN $35.93
- BIIB $153.62
- 52 Week High
- DVN $55.09
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- DVN 27.99
- BIIB 35.55
- Support Level
- DVN $37.15
- BIIB $158.31
- Resistance Level
- DVN $38.37
- BIIB $162.62
- Average True Range (ATR)
- DVN 0.86
- BIIB 3.00
- MACD
- DVN -0.26
- BIIB 1.00
- Stochastic Oscillator
- DVN 2.26
- BIIB 48.60
About DVN Devon Energy Corporation
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2023, Devon reported net proved reserves of 1.8 billion barrels of oil equivalent. Net production averaged roughly 658,000 barrels of oil equivalent per day in 2023 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.